Souhaitez-vous accéder aux communiqués récents ?

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for granting an exclusive worldwide license to the program, Nxera...

Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”)...

– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003; MHLW...

Following IDMC recommendation after interim futility analysis the decision was made to discontinue the TACTI-004 Phase III trialRoot cause analysis is ongoing and implications for the broader...

Robert J. Dempsey, MBA, Chief Executive Officer, to present at EyeceleratorRaj Patil, PhD, Chief Scientific Officer, to present at ARVO LONDON and NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- OKYO...

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia...

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia...

Potent and durable efficacy with iSCIB1+ of 77% progression free survival (PFS) at 20 months, in combination with ipilimumab and nivolumab, demonstrated in the Phase 2 SCOPE trial; more PFS and...

Promatix Highlights the Power of its Logic-Gated Proteomics-Driven Bispecific Discovery Platform to Expand the Tumour-Selective Target Space for ADCs

This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipelineUnder the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in...